Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) [Yahoo! Finance]
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid [Seeking Alpha]
Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript [Seeking Alpha]